• Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results

    Источник: Nasdaq GlobeNewswire / 22 мар 2022 08:00:03   America/New_York

    PURCHASE, N.Y., March 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2021 on Wednesday, March 30, 2022 before market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update.

    Conference Call Information:

    Telephone
    Access:
    US/Canada Participant Toll-Free Dial-in Number: (844) 467-7752
    US/Canada Participant International Dial-In Number: (270) 215-9364
    Conference ID Number: 7048915
      
    Webcast
    Access:
    The audio webcast with live Q&A will be accessible via theInvestor Relationssection of Cognition’s website. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on Wednesday, March 30, 2022.
      

    About Cognition Therapeutics:
    Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the sigma-2 (σ-2) receptor, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the σ-2 receptor complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at www.sec.gov.You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    Contact Information:
    Cognition Therapeutics, Inc.
    info@cogrx.com

    Aline Sherwood (media)
    Scienta Communications
    asherwood@scientapr.com

    Lisa Sher/Daniel Kontoh-Boateng (investors)
    Tiberend Strategic Advisors, Inc.
    lsher@tiberend.com
    dboateng@tiberend.com


    Primary Logo

Опубликовать